vimarsana.com

Page 4 - ஹிசாமிட்சு மருந்து இணை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Noven to Present Pivotal Study Results for Investigational Dextroamphetamine Transdermal System for Pediatric ADHD Patients

Press release content from Business Wire. The AP news staff was not involved in its creation. Noven to Present Pivotal Study Results for Investigational Dextroamphetamine Transdermal System for Pediatric ADHD Patients April 27, 2021 GMT MIAMI & JERSEY CITY, N.J. (BUSINESS WIRE) Apr 27, 2021 Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced it will present the results of a multicenter, phase 2, laboratory classroom study which evaluated the safety and efficacy of its investigational dextroamphetamine transdermal system (“ATS”) in over 100 pediatric patients (ages 6-17 years) with ADHD at the 2021 virtual American Psychiatric Association (APA) Annual Meeting May 1-3, 2021.

Hisamitsu America, Marketers of the Salonpas Line of Pain-Relieving Products, Announce Launch of Salonpas(R) Arthritis Pain Relief Gel

(1) FLORHAM PARK, NJ / ACCESSWIRE / March 1, 2021 / Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the Salonpas ® line of pain-relieving products, announce the availability of the Salonpas® Arthritis Pain Relief Gel, which features the most prescribed topical pain medicine clinically proven to relieve arthritis pain in major joints. That medicine is prescription-strength diclofenac, which was approved by the FDA for over-the-counter (OTC) use in 2020. Salonpas ® has a long history of driving growth through our scientific approach to pain relief which includes providing the first FDA-approved OTC topical pain reliever to the public in 2008, said John Incledon, President & CEO, Hisamitsu America. Our science-based approach is critical to our support of the

Hormone Replacement Therapy Market to Reach $46 50 Bn, Globally, by 2027 at 5 1% CAGR: Allied Market Research

Hormone Replacement Therapy Market to Reach $46 50 Bn, Globally, by 2027 at 5 1% CAGR: Allied Market Research
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.